AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review

Region:Europe

Author(s):

Product Code:GDPH3904FSA

Download Sample Report download
Buy the Full ReportStarting from $125
Published on

March 2019

Total pages

88

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $125

About the Report

About the Report

AstraZeneca Plc (AZN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas including respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

AstraZeneca Plc Key Recent Developments

Mar 25,2019 AstraZeneca's Forxiga garners EU approval in type 1 diabetes

Mar 25,2019 EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes

Mar 14,2019 AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting

Mar 14,2019 AstraZeneca: Appointment of M s. Sarah Wang as an additional director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Products

Products

AstraZeneca Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

AstraZeneca Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

Table of Contents

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

AstraZeneca Plc-Key Facts

AstraZeneca Plc-Key Employees

AstraZeneca Plc-Key Employee Biographies

AstraZeneca Plc-Major Products and Services

AstraZeneca Plc-History

AstraZeneca Plc-Company Statement

AstraZeneca Plc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

AstraZeneca Plc-Business Description

Business Segment: Biopharmaceuticals

Overview

Performance

Business Segment: Externalisation Revenue

Overview

Performance

Geographical Segment: Asia, Africa & Australasia

Target Markets

Performance

Geographical Segment: Continental Europe

Target Markets

Performance

Geographical Segment: The Americas

Target Markets

Performance

Geographical Segment: UK

Performance

R&D Overview

AstraZeneca Plc-Corporate Strategy

AstraZeneca Plc-SWOT Analysis

SWOT Analysis-Overview

AstraZeneca Plc-Strengths

AstraZeneca Plc-Weaknesses

AstraZeneca Plc-Opportunities

AstraZeneca Plc-Threats

AstraZeneca Plc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

AstraZeneca Plc, Recent Deals Summary

Section 5-Company's Recent Developments

Mar 25, 2019: AstraZeneca's Forxiga garners EU approval in type 1 diabetes

Mar 25, 2019: EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes

Mar 14, 2019: AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting

Mar 14, 2019: AstraZeneca: Appointment of M s. Sarah Wang as an additional director

Mar 12, 2019: AstraZeneca, Seres Therapeutics to study new cancer therapy approach

Mar 11, 2019: AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019

Feb 27, 2019: Top pharma executives testify before US Senate over high prices

Feb 20, 2019: Study on regenerative angiogenesis in humans shows encouraging results

Feb 14, 2019: AstraZeneca announces full-year and Q4 2018 results

Feb 14, 2019: MedImmune brand to be retired as biologics integrate into AstraZeneca's new R&D structure

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List of Figure

List of Figures

AstraZeneca Plc, Performance Chart (2014-2018)

AstraZeneca Plc, Ratio Charts

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List of Table

List of Tables

AstraZeneca Plc, Key Facts

AstraZeneca Plc, Key Employees

AstraZeneca Plc, Key Employee Biographies

AstraZeneca Plc, Major Products and Services

AstraZeneca Plc, History

AstraZeneca Plc, Subsidiaries

AstraZeneca Plc, Joint Venture

AstraZeneca Plc, Key Competitors

AstraZeneca Plc, Ratios based on current share price

AstraZeneca Plc, Annual Ratios

AstraZeneca Plc, Annual Ratios (Cont...1)

AstraZeneca Plc, Annual Ratios (Cont...2)

AstraZeneca Plc, Interim Ratios

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

AstraZeneca Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022